Bleeding risk of surgical versus medical abortion at 14–16 weeks
Late-term Abortions Between 14 and 16 Weeks of Gestation: Comparison of Hemorrhagic Risks in Surgical vs. Medical Abortions
University Hospital, Strasbourg, France · NCT07335939
This project tests whether surgical or medical abortion causes less bleeding for adults having an abortion at 14–16 weeks of pregnancy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 40 Years |
| Sex | Female |
| Sponsor | University Hospital, Strasbourg, France (other) |
| Locations | 1 site (Strasbourg) |
| Trial ID | NCT07335939 on ClinicalTrials.gov |
What this trial studies
This is an observational comparison of hemorrhagic outcomes after surgical versus medical abortion for pregnancies between 14 and 16 weeks at Strasbourg University Hospital. The team will collect clinical data from patients treated between March 2, 2022 and March 2, 2026, including single and multiple pregnancies. Outcomes will focus on rates of bleeding complications and severe hemorrhage associated with each method. Results aim to clarify risks and support method choice in the extended legal time window.
Who should consider this trial
Good fit: Adult women with a single or multiple ongoing pregnancy who undergo an abortion at 14–16 weeks of gestation at Strasbourg University Hospital between March 2, 2022 and March 2, 2026.
Not a fit: People with pregnancies under 14 weeks, over 16 weeks, missed pregnancies, or those treated outside CHU Strasbourg or outside the study dates are not included and would not directly benefit from this project's data.
Why it matters
Potential benefit: If successful, the findings could give clearer information to reduce bleeding complications and help people choose the safer method at 14–16 weeks.
How similar studies have performed: Prior research and French guidance generally favor surgical methods after early gestation due to lower bleeding risk, but direct comparative data specifically for 14–16 weeks are limited and mixed.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult woman * Single or multiple pregnancy * Undergoing an abortion between 14 and 16 weeks of gestation at the Strasbourg University Hospital between March 2, 2022, and March 2, 2026 Exclusion Criteria: * Missed Pregnancy * Term \< 14 Weeks of Gestation or \> 16 Weeks of Gestation
Where this trial is running
Strasbourg
- Service de Gynécologie-Obstétrique - CHU de Strasbourg - France — Strasbourg, France (RECRUITING)
Study contacts
- Study coordinator: Victor Gabrielle, MD
- Email: Victor.gabriele@chru-strasbourg.fr
- Phone: 33 3 69 55 34 04
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Abortion Late, Ongoing single pregnancy, Ongoing multiple pregnancy